Tag

Huntingtons Disease

All articles tagged with #huntingtons disease

Monogenic diseases aren’t deterministic: context shapes genetic risk
health5 hours ago

Monogenic diseases aren’t deterministic: context shapes genetic risk

New population-genomics research shows that many so-called monogenic diseases do not have 100% penetrance; a person carrying a disease-associated variant may remain healthy depending on other genetic factors and environment. Large datasets reveal that variants once believed to almost always cause conditions like inherited retinal degenerations, thyroid cancer, ovarian insufficiency, and even Huntington's disease do not guarantee disease in the general population, highlighting the need for nuanced genetic counseling and individualized risk assessments and potentially informing advances in gene therapies and embryo selection.

Promising Gene Therapy Hints at Slowing Huntington's Disease Progression
science1 month ago

Promising Gene Therapy Hints at Slowing Huntington's Disease Progression

A small trial of uniQure’s AMT-130 gene therapy in 29 Huntington’s disease patients showed reduced production of the mutant huntingtin protein, slower cognitive decline, and lower levels of neurofilament light in cerebrospinal fluid over three years, suggesting a potential disease-modifying effect. Results were reported in a press release and have not yet undergone peer review, but they point to a possible treatment that could be used earlier in the disease course, while researchers continue to identify early biomarkers and expand the treatment window before motor symptoms appear.

uniQure's AMT-130 Regulatory Uncertainty Sparks Hope for Huntington’s Disease
healthcare3 months ago

uniQure's AMT-130 Regulatory Uncertainty Sparks Hope for Huntington’s Disease

uniQure announced that the FDA no longer considers Phase I/II data versus an external control sufficient as primary evidence for a BLA submission for its Huntington's disease gene therapy AMT-130, creating uncertainty about the approval timeline. The company plans urgent discussions with the FDA and continues regulatory engagement in the EU and UK, despite holding breakthrough therapy and RMAT designations.